Top Stocks for 2024 Smart Score

This is a China news story, published by Yahoo Finance, that relates primarily to Keytruda news.

China news

For more China news, you can click here:

more China news

Keytruda news

For more Keytruda news, you can click here:

more Keytruda news

stocks trading & speculation news

For more stocks trading & speculation news, you can click here:

more stocks trading & speculation news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about

top stocks

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest TipRanks databanks news, Best Stocks news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

BOOT stock forecast

TipRanks

•

TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks for the Rest of 2024

Summary

Nutrition label

81% Informative

TipRanks ' Smart Score is based on the stock's standing against a set of factors known to match up with future outperformance.

Boot Barn Holdings (BOOT) and Summit Therapeutics (SMMT) are two of the top-scoring stocks that investors should consider for the rest of 2024 .

The Perfect 10 are stocks that have earned the highest possible Smart Score .

Summit's Ivonescimab beats the results of Merck ’s anti-cancer drug, Keytruda .

The drug was tested in a Phase 3 trial, HARMONi-2 , conducted in China , and showed that it could reduce the risk of disease progression or death by 49% when compared to the Merck drug.

JMP analyst Reni Benjamin rates SMMT shares an Outperform (i.e. Buy ), while his $ 32 price target implies a 50% gain for the next 12 months .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech